Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$1.62 USD
-0.06 (-3.57%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $1.64 +0.02 (1.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Autolus Therapeutics PLC Sponsored ADR's return on equity, or ROE, is -56.18% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that AUTL has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
AUTL 1.62 -0.06(-3.57%)
Will AUTL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AUTL
AUTL's price falls by 2.33% on October 16, though its technical setup remains stable.
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush
Crossed Above 50 Day Moving Average appears for AUTL after 6.17% move
Needham Hosts Virtual Meeting Featuring AUTL on October 22